Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue-
EPS-$2.11Miss by $0.03
EPS estimate-$2.08

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$2.50

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$30.9M+38.1%
Net income-$32.8M—
EPS (diluted)-$2.11—

Balance sheet

See full
Cash & equivalents$124.2M-18.6%
Total debt$107.0M+1,230%
Total equity$8.0M-94.0%
Total assets$146.5M-19.0%

Cash flow

See full
Operating cash flow-$30.1M+31.1%
Free cash flow-$30.1M+31.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.15B+415%
Enterprise value$1.13B+1,344%
P/S883.8×-231×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio3.9×0.0×

FAQ

When did Inhibrx Biosciences, Inc. report Q4 2025 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Inhibrx Biosciences, Inc.'s Q4 2025 revenue and EPS?
Inhibrx Biosciences, Inc. reported revenue of - and eps of $-2.11 for Q4 2025.
Did Inhibrx Biosciences, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-2.08 by $0.03.
How did Inhibrx Biosciences, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $100.0K a year earlier and eps grew 31.7% from $-3.09.
Where can I find Inhibrx Biosciences, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0002007919-26-000007) and the 10-K periodic report (0002007919-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.